Poseida Therapeutics (PSTX) announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D., currently President, Cell Therapy, to the role of President and CEO, each expected to be effective January 1, 2024. Now in her third decade in the biopharmaceutical industry, Dr. Yarema joined the company as President of Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. Prior to Poseida she served as Chief Commercial Officer at Atara Biotherapeutics (ATRA) where she led the commercialization of EBVALLO, which became the world’s first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
